Suppr超能文献

尿激酶通过尿激酶受体依赖性上调平滑肌细胞与玻连蛋白的黏附

Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.

作者信息

Chang A W, Kuo A, Barnathan E S, Okada S S

机构信息

University of Pennsylvania School of Medicine, Philadelphia, USA.

出版信息

Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1855-60. doi: 10.1161/01.atv.18.12.1855.

Abstract

The plasminogen activator system has been implicated in the modulation of the response to vascular injury. Although urokinase-type plasminogen activator (uPA) and its receptor (uPAR) may enhance matrix degradation as well as migration and invasion by smooth muscle cells (SMCs), their roles in cell adhesion are uncertain. Therefore, we examined the ability of uPA and uPAR to modulate adhesion of cultured human vascular SMCs to various matrices. We demonstrated a dose-dependent stimulation of adhesion by single-chain uPA (scuPA) to vitronectin (maximum 1.55-fold [+/-0. 04-fold] increase, 10 nmol/L, P<0.002) but not to laminin, collagen I, or collagen IV. Baseline adhesion to vitronectin was completely inhibited by both EDTA and RGD peptide but was restored to >40% of control in the presence of scuPA (P=0.001 and 0.046, respectively). Adhesion to vitronectin was also significantly enhanced by the amino-terminal fragment of uPA (P=0.007) and two-chain, high-molecular-weight uPA (P<0.01) but not by the low-molecular-weight fragment of uPA, which lacks the receptor-binding domain. Aprotinin, a plasmin inhibitor, had no effect on baseline or scuPA-stimulated adhesion, suggesting a plasmin-independent process. Preincubation of scuPA with soluble uPAR inhibited scuPA stimulation of adhesion by 88+/-14% (P=0.01), as did pretreatment of SMCs with phosphatidylinositol-specific phospholipase C, which removes glycophosphatidylinositol-anchored proteins, including uPAR. Antibodies to both alphavbeta3 and alphavbeta5 integrin inhibited baseline adhesion but not scuPA stimulation. Finally, coating plates with scuPA alone enabled cell adhesion, which could be inhibited by both soluble uPAR and anti-uPAR antibodies. These data suggest that uPA stimulates adhesion of SMCs specifically to vitronectin and that it is mediated by an interaction with uPAR. Upregulation of both proteins after vascular injury may facilitate migration through stimulation of both matrix degradation and cell adhesion.

摘要

纤溶酶原激活物系统与血管损伤反应的调节有关。尽管尿激酶型纤溶酶原激活物(uPA)及其受体(uPAR)可能会增强基质降解以及平滑肌细胞(SMC)的迁移和侵袭,但它们在细胞黏附中的作用尚不确定。因此,我们研究了uPA和uPAR调节培养的人血管SMC与各种基质黏附的能力。我们证明了单链uPA(scuPA)对玻连蛋白的黏附具有剂量依赖性刺激作用(最大增加1.55倍[±0.04倍],10 nmol/L,P<0.002),但对层粘连蛋白、I型胶原或IV型胶原无此作用。EDTA和RGD肽均可完全抑制对玻连蛋白的基础黏附,但在scuPA存在的情况下可恢复至对照的>40%(分别为P=0.001和0.046)。uPA的氨基末端片段(P=0.007)和双链、高分子量uPA(P<0.01)也可显著增强对玻连蛋白的黏附,但缺乏受体结合域的uPA低分子量片段则无此作用。纤溶酶抑制剂抑肽酶对基础黏附或scuPA刺激的黏附均无影响,提示这是一个不依赖纤溶酶的过程。用可溶性uPAR预孵育scuPA可使scuPA对黏附的刺激作用降低88±14%(P=0.01),用磷脂酰肌醇特异性磷脂酶C预处理SMC也有同样效果,该酶可去除包括uPAR在内的糖磷脂酰肌醇锚定蛋白。抗αvβ3和αvβ5整合素抗体可抑制基础黏附,但不能抑制scuPA刺激。最后,仅用scuPA包被平板可使细胞黏附,可溶性uPAR和抗uPAR抗体均可抑制这种黏附。这些数据表明,uPA可特异性刺激SMC与玻连蛋白的黏附,且这一过程由与uPAR的相互作用介导。血管损伤后这两种蛋白的上调可能通过刺激基质降解和细胞黏附来促进迁移。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验